Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.45 |
| ▸ | MC4R | P32245 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 2/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.41 |
| ▸ | RHOC | P08134 | 4/20 | 0.41 |
| ▸ | RHOA | P61586 | 4/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SPTLC2 | O15270 | 1/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13814651 | 1.00 | TACR1 (0.45) | TACR1MC4RSTSUSP30DDR1 | |
| SCHEMBL13814606 | 0.94 | TACR1 (0.47) | TACR1STSUSP30HDAC4HDAC6 | |
| SCHEMBL13801622 | 0.94 | TACR1 (0.47) | TACR1STSUSP30HDAC4HDAC6 | |
| SCHEMBL13801601 | 0.94 | TACR1 (0.50) | TACR1MC4RSTSUSP30RHOC | |
| SCHEMBL13814653 | 0.94 | TACR1 (0.50) | TACR1MC4RSTSUSP30RHOC | |
| SCHEMBL13801602 | 0.92 | TACR1 (0.46) | TACR1STSUSP30HDAC4HDAC6 | |
| SCHEMBL13814602 | 0.92 | TACR1 (0.46) | TACR1STSUSP30HDAC4HDAC6 | |
| SCHEMBL13814677 | 0.92 | TACR1 (0.46) | TACR1STSUSP30HDAC4HDAC6 | |
| SCHEMBL13801594 | 0.92 | TACR1 (0.46) | TACR1STSUSP30HDAC4HDAC6 | |
| SCHEMBL13801586 | 0.92 | TACR1 (0.44) | TACR1STSUSP30HDAC4HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470816-B2 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | TACR1 9/4885MC4R 128/4885STS 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.